• Markets
  • icon
  • Companies
ATX · ASX

Amplia Therapeutics Ltd. (ASX:ATX)

AU$0.058

 -0.0025 (-4.132%)
ASX:Live
17/05/2024 04:10:34 PM
Hammer Bearish HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

ATX Overview

ATX Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ATX

Telephone

Address

Description

Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia.

ATX Price Chart

Key Stats

Market Cap

AU$16.43M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.09

Trade Value (12mth)

AU$1,712.00

1 week

1.75%

1 month

-4.92%

YTD

-26.32%

1 year

-29.79%

All time high

16.278600692749023

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

194m

HALO Sector

Next Company Report Date

27-May-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ATX Announcements

Latest Announcements

Date Announcements

16 May 24

Becoming a substantial holder from PCG

×

Becoming a substantial holder from PCG

16 May 24

Change in substantial holding

×

Change in substantial holding

16 May 24

Notification regarding unquoted securities - ATX

×

Notification regarding unquoted securities - ATX

16 May 24

Becoming a substantial holder from SOL

×

Becoming a substantial holder from SOL

15 May 24

$4.27m Offer Successfully Completed and ACCENT Trial Update

×

$4.27m Offer Successfully Completed and ACCENT Trial Update

15 May 24

Application for quotation of securities - ATX

×

Application for quotation of securities - ATX

15 May 24

Substantial Holder Notice - Blueflag Holding Pty Ltd

×

Substantial Holder Notice - Blueflag Holding Pty Ltd

13 May 24

Notification of cessation of securities - ATX

×

Notification of cessation of securities - ATX

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

24 April 24

Entitlement Offer - Offer Booklet

×

Entitlement Offer - Offer Booklet

16 April 24

Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27

×

Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27

16 April 24

Rights Issue Investor Slide Deck

×

Rights Issue Investor Slide Deck

16 April 24

Entitlement Offer Cleansing Statement

×

Entitlement Offer Cleansing Statement

16 April 24

Proposed issue of securities - ATX

×

Proposed issue of securities - ATX

12 April 24

Trading Halt

×

Trading Halt

10 April 24

AACR Conference Presentation

×

AACR Conference Presentation

27 March 24

Update on ACCENT Trial in Pancreatic Cancer

×

Update on ACCENT Trial in Pancreatic Cancer

30 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

18 January 24

FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US

×

FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US

17 January 24

Amplia Reports First Patient Dosing In Phase 2a Accent Trial

×

Amplia Reports First Patient Dosing In Phase 2a Accent Trial

17 January 24

Pause in Trading

×

Pause in Trading

17 January 24

Trading Halt

×

Trading Halt

02 January 24

Application for quotation of securities - ATX

×

Application for quotation of securities - ATX

02 January 24

Notification of cessation of securities - ATX

×

Notification of cessation of securities - ATX

02 January 24

Change of Director's Interest Notice - Jane Bell

×

Change of Director's Interest Notice - Jane Bell

ATX Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.02 N/A Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.02 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 43.2 -5.0 N/A Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.02 N/A Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.3 -4.6 N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock -11.9 -20.9 N/A Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.09 0.11 N/A Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.07 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 139.4 226.0 N/A Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 96 146 N/A Lock Lock Lock
Basic m Lock Lock Lock Lock 96 146 N/A Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 6 N/A Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.1 -377.5 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -6 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.6 -45.2 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -6 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.5 -45.2 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -4 -6 N/A Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 N/A Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -4 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -2.8 -59.8 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -4 N/A Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 4 17 N/A Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -4 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -39.9 -51.2 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 15 N/A Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 11 24 N/A Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 2 N/A Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -13 N/A Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 3 N/A Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 22 N/A Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 24 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.2 131.6 N/A Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.0 -14.9 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.1 -16.7 N/A Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -40.9 -32.8 N/A Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -24.1 -21.3 N/A Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -30.8 -25.7 N/A Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A -4,890.3 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.5 2.2 N/A Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -17.9 -57.3 N/A Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.4 31.2 N/A Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.4 31.2 N/A Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 63.0 88.4 N/A Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -540.9 -830.3 N/A Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 N/A Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.0 -14.9 N/A Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.1 -16.7 N/A Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 N/A Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -22.1 -16.7 N/A Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 243,333.3 44,512.2 N/A Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -243,333.3 -44,512.2 N/A Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ATX Shortsell

Frequently Asked Questions

The current share price of Amplia Therapeutics Ltd. (ATX:ASX) is AU$0.058.
The 52-week high share price for Amplia Therapeutics Ltd. (ATX:ASX) is AU$0.09.
The 52-week low share price for Amplia Therapeutics Ltd. (ATX:ASX)? is AU$0.05.
Amplia Therapeutics Ltd. (ATX:ASX) does not pay a dividend.
Amplia Therapeutics Ltd. (ATX:ASX) does not pay a dividend.
Amplia Therapeutics Ltd. (ATX:ASX) has a franking level of 0.0%.
Amplia Therapeutics Ltd. (ATX:ASX) is classified in the Healthcare.
The current P/E ratio for Amplia Therapeutics Ltd. (ATX:ASX) is .